Drilldown: Medicines
Medicines > classes 
:
Dissociative or
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]]
:
Dissociative or
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] Use the filters below to narrow your results.
generic:
None (1) ·
2-FDCK (1) ·
3-HO-PCE (1) ·
3-HO-PCP (1) ·
3-MeO-PCE (1) ·
3-MeO-PCP (1) ·
4-MeO-PCP (1) ·
Dapagliflozin (1) ·
Deschloroketamine (1) ·
Dextromethorphan (1) ·
Dextrorphan (1) ·
Diphenidine (1) ·
Empagliflozin (1) ·
Ephenidine (1) ·
Eticyclidine (1) ·
Glimepiride (1) ·
Glipizide (1) ·
Ibogaine (1) ·
Linagliptin (1) ·
Metformin (1) ·
Methoxetamine (1) ·
Nitrous oxide (1) ·
O-PCE (1) ·
Pioglitazone (1) ·
Salvia divinorum (1) ·
Salvinorin A (1) ·
Sitagliptin (1) ·
Xenon (1)
brand:
None (17) ·
Actos (1) ·
Amaryl (1) ·
DXM (1) ·
DXO (1) ·
Farxiga (US), Forxiga (international) (1) ·
Glucophage, Glucophage XR, Fortamet, Glumetza, Riomet (1) ·
Glucotrol, Glucotrol XL (1) ·
Januvia; with metformin Janumet/Janumet XR (1) ·
Jardiance (1) ·
Spravato (1) ·
Tradjenta; with metformin Jentadueto (1)
classes: (Click arrow to add another value)
mechanism:
None (6) ·
Active metabolite of DXM; NMDA antagonist (1) ·
Contains salvinorin A (1) ·
Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) ·
Kappa-opioid receptor agonist (1) ·
NMDA antagonist (3) ·
NMDA antagonist; endogenous opioid releaser (1) ·
NMDA antagonist; fluorinated ketamine analogue (1) ·
NMDA antagonist; kappa-opioid agonist (1) ·
NMDA antagonist; ketamine analogue (1) ·
NMDA antagonist; more stimulating than PCP (1) ·
NMDA antagonist; opioid agonist (1) ·
NMDA antagonist; potent opioid agonist (1) ·
NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) ·
NMDA antagonist; sigma receptor agonist (2) ·
NMDA antagonist; sigma receptor agonist; dopaminergic (1) ·
NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) ·
'"`UNIQ--vote-00000013-QINU`"' Does not stimulate insulin secretion; minimal hypoglycemia risk as monotherapy. Cleared renally unchanged; dose-adjust by eGFR'"`UNIQ--ref-00000014-QINU`"'. Rare lactic acidosis primarily in renal failure or acute illness. (1) ·
'"`UNIQ--vote-000002D7-QINU`"' Hypoglycemia is the central risk, especially in elderly and renally impaired patients (glipizide has shorter half-life than glyburide, which is one reason it is preferred in older adults). CYP2C9 substrate; weight gain typical. (1) ·
'"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1)
uses:
None (19) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) ·
'"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"', '"`UNIQ--vote-00000017-QINU`"' (1) ·
'"`UNIQ--vote-00000278-QINU`"', '"`UNIQ--vote-00000279-QINU`"', '"`UNIQ--vote-0000027A-QINU`"', '"`UNIQ--vote-0000027B-QINU`"' (1) ·
'"`UNIQ--vote-000002D8-QINU`"' (1) ·
'"`UNIQ--vote-00000491-QINU`"' (1) ·
'"`UNIQ--vote-0000054E-QINU`"', '"`UNIQ--vote-0000054F-QINU`"', '"`UNIQ--vote-00000550-QINU`"', '"`UNIQ--vote-00000551-QINU`"' (1) ·
'"`UNIQ--vote-00000764-QINU`"' (1) ·
'"`UNIQ--vote-00000822-QINU`"', '"`UNIQ--vote-00000823-QINU`"' (1) ·
'"`UNIQ--vote-0000117B-QINU`"' (1)
starting dose:
None (19) ·
1-2 mg PO once daily with breakfast; titrate by glycemic response (1) ·
10 mg PO once daily in the morning; 5 mg starting in heart failure (1) ·
10 mg PO once daily in the morning; may titrate to 25 mg for additional glycemic effect (1) ·
100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis) (1) ·
15-30 mg PO once daily; titrate to 45 mg (1) ·
5 mg PO once daily (no renal dose adjustment, unlike sitagliptin) (1) ·
5 mg PO once daily, 30 minutes before breakfast; XL: 5 mg with breakfast (1) ·
500 mg PO once or twice daily with meals; titrate weekly to limit GI effects (1) ·
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
None (19) ·
1 mg, 2 mg, 4 mg tablets (1) ·
10 mg, 25 mg tablets (1) ·
15, 30, 45 mg tablets (1) ·
25, 50, 100 mg tablets; combination tablets with metformin (1) ·
28 mg/device (each dose uses 2 devices) (1) ·
5 mg tablets; combination with metformin (1) ·
5 mg, 10 mg immediate-release tablets; 2.5 mg, 5 mg, 10 mg extended-release tablets (1) ·
5 mg, 10 mg tablets (1) ·
500 mg, 850 mg, 1000 mg IR tablets; 500 mg, 750 mg, 1000 mg ER tablets; 500 mg/5 mL oral solution (1)
fda max:
onset:
None (19) ·
1-2 hours (1) ·
Glucose lowering within days; HbA1c effect at 8-12 weeks (1) ·
Glycosuria within hours; HbA1c effect at 12 weeks; cardiovascular and renal benefits over months (1) ·
Glycosuria within hours; HbA1c effect at 12 weeks; CV/renal benefits over months (1) ·
HbA1c effect at 12-16 weeks (slower than other classes) (1) ·
Postprandial glucose effect within days; HbA1c by 12 weeks (2) ·
Within 30 minutes (IR) (1) ·
Within hours of first administration (1)
duration:
halflife:
None (19) ·
2-5 hours'"`UNIQ--ref-000002D9-QINU`"' (1) ·
6.2 hours (plasma); ~17 hours in erythrocytes'"`UNIQ--ref-00000018-QINU`"' (1) ·
~12 hours (effective); terminal much longer'"`UNIQ--ref-0000117C-QINU`"' (1) ·
~12.4 hours'"`UNIQ--ref-0000027C-QINU`"' (1) ·
~12.4 hours'"`UNIQ--ref-00000765-QINU`"' (1) ·
~12.9 hours'"`UNIQ--ref-00000552-QINU`"' (1) ·
~3-7 hours (parent); 16-24 hours including active metabolites'"`UNIQ--ref-00000824-QINU`"' (1) ·
~5-9 hours (parent and active metabolites combined)'"`UNIQ--ref-00000492-QINU`"' (1) ·
~7-12 hours (1)
bioavailability:
None (19) ·
50-60% (oral; decreased with food, but food given anyway for GI tolerance)'"`UNIQ--ref-00000019-QINU`"' (1) ·
High (oral; absorption not affected by food)'"`UNIQ--ref-00000825-QINU`"' (1) ·
High (oral; not affected by food, but typically given with the morning meal)'"`UNIQ--ref-0000027D-QINU`"' (1) ·
~100% (oral; food delays absorption, hence pre-meal dosing for IR)'"`UNIQ--ref-000002DA-QINU`"' (1) ·
~100% (oral; not significantly affected by food)'"`UNIQ--ref-00000493-QINU`"' (1) ·
~30% (oral)'"`UNIQ--ref-0000117D-QINU`"' (1) ·
~48% intranasal (1) ·
~78% (oral; high-fat meal modestly reduces but is not clinically significant)'"`UNIQ--ref-00000553-QINU`"' (1) ·
~87% (oral)'"`UNIQ--ref-00000766-QINU`"' (1)
pregnancy:
None (19) ·
Avoid in second and third trimesters; fetal SGLT2 inhibition disrupts kidney development.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Avoid; may cause fetal harm (1) ·
Avoid; switch to insulin. Hypoglycemia in newborn reported.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Avoid; switch to insulin. Neonatal hypoglycemia reported.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; widely used in PCOS and gestational diabetes; placental transfer occurs.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (3)
legal:
None (19) ·
Rx, Schedule III (US). REMS program required. (1) ·
[[USLegal:Prescription only|Rx-only]] in US (7) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for heart failure (do not initiate in NYHA III/IV; can precipitate or worsen HF in any patient)'"`UNIQ--ref-00000826-QINU`"' (1)
Showing below up to 28 results in range #1 to #28.